Have you or your loved ones been diagnosed with brain and central nervous system tumors?

You may be eligible to participate in a brain and central nervous system tumors clinical trial.

Have you or your loved ones been diagnosed with brain and central nervous system tumors? You may be eligible to participate in a brain and central nervous system tumors clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Brain and Central Nervous System Tumors Clinical Trial in Detroit MI

NCT00935090 | Interventional

Have you or your loved ones been diagnosed with brain and central nervous system tumors?

You may be eligible to participate in a brain and central nervous system tumors clinical trial.

Have you or your loved ones been diagnosed with brain and central nervous system tumors? You may be eligible to participate in a brain and central nervous system tumors clinical trial.

Suspended

Male & Female

18 - 120

Years old

This study is looking to recruit 80 Participants

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

Show me more details

Details for the study

Brief Title

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Official Title

Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)

Brief Summary

RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET <br /> imaging, may help find and diagnose cancer. It may also help doctors predict a patient's <br /> response to treatment and help plan the best treatment. <br /> <br /> PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.

Detailed Description

OBJECTIVES:

Primary

- Evaluate the use of 3'-deoxy-3'-[18F] fluorothymidine (FLT) positron emission tomography
(PET) imaging to measure tumor proliferation and the DNA synthetic pathway (thymidine
kinase levels) in patients with cancer.

Secondary

- Determine the efficacy of FLT PET imaging in detecting lesions and estimating response
to treatment.

OUTLINE: Patients undergo up to four 3'-deoxy-3'-[18F] fluorothymidine positron emission
tomography imaging procedures.

Treatments and/or Procedures

3' deoxy 3' [18F]fluorothymidine

The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.

Study Criteria

DISEASE CHARACTERISTICS:

  -  Meets one of the following criteria:

       -  Histologically confirmed solid tumor or hematologic malignancy

       -  Awaiting biopsy or surgery for cancer evaluation of a mass detected on exam or
          standard imaging

PATIENT CHARACTERISTICS:

  -  Able to lie still in the PET scanner

  -  Girth and weight must be suitable to enter the gantry

  -  Not pregnant or nursing

  -  Negative pregnancy test

  -  Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

  -  Not specified